Comparative Pharmacology
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus NESACAINE MPF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus NESACAINE MPF.
LIDOSITE TOPICAL SYSTEM KIT vs NESACAINE-MPF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
Nesacaine-MPF (chloroprocaine) is an ester-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking impulse conduction in nerve fibers.
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
1% solution: 2.5-30 mL (25-300 mg) subcutaneously or locally; maximum 30 mL per dose. 2% solution: 1.25-15 mL (25-300 mg) subcutaneously or locally; maximum 15 mL per dose.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Terminal half-life: 3-4 hours (adults); prolonged in hepatic or renal impairment.
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Renal excretion of metabolites; <10% unchanged drug. Biliary/fecal elimination minor.
Category C
Category C
Local Anesthetic
Local Anesthetic